de Andrade, Pedro BeraldoTebet, Marden AndréNogueira, Ederlon Ferreirade Andrade, Mônica Vieira AthanazioBarbosa, Robson AlvesLabrunie, André [UNESP]Mattos, Luiz Alberto2014-05-272014-05-272012-06-01Revista Brasileira de Cardiologia Invasiva, v. 20, n. 2, 2012.0104-1843http://hdl.handle.net/11449/73352Background: Fondaparinux is considered an agent with a well-established safety and efficacy profile in the treatment of non-ST segment elevation acute coronary syndromes, but when used alone, is associated to a higher incidence of thrombotic complications during invasive coronary procedures, requiring the supplementation of an anti-IIa agent. This study aimed to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) in patients with non-ST segment elevation acute coronary syndromes previously treated with fondaparinux. Methods: Prospective, controlled registry enrolling 127 consecutive patients submitted to an early invasive stratification during treatment with fondaparinux, with supplementation of intravenous unfractionated heparin at a dose of 85 U/kg at the time of PCI. Results: The rate of the composite primary endpoint including death, acute myocardial infarction, stroke, stent thrombosis or emergency myocardial revascularization was 3.2%. The cumulative incidence of major bleeding and vascular complications was 3.2%. There were no cases of guidecatheter thrombosis or abrupt vessel closure. Conclusions: PCI in patients with acute coronary syndromes receiving fondaparinux is associated with a low rate of major adverse cardiovascular ischemic events and severe hemorrhagic complications. Supplementation of unfractionated heparin during the invasive procedures eliminates the risk of catheter-related thrombosis.engAcute coronary syndromeAngioplastyAnticoagulantsFondaparinuxStentsfondaparinuxheparinacute coronary syndromeacute heart infarctionbleedingcatheter thrombosisclinical trialdeathdisease associationdrug efficacydrug safetyemergency careheart muscle ischemiahumanmajor clinical studynon st segment elevation acute coronary syndromepercutaneous coronary interventionprospective studyrevascularizationstent thrombosisstrokevascular diseaseArtigo10.1590/S2179-83972012000200008S2179-83972012000200008Acesso aberto2-s2.0-848637376922-s2.0-84863737692.pdf